Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates

Heron Therapeutics (HRTX) PT Lowered to $20 at Cantor Fitzgerald

March 1, 2022 7:22 AM EST

Cantor Fitzgerald analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $20.00 (from $26.00) while maintaining a Neutral rating.

... More

Heron Therapeutics (HRTX) PT Lowered to $13 at Cowen

March 1, 2022 6:54 AM EST

Cowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $13.00 (from $31.00) while maintaining an Outperform rating following disappointing Q4 results.

The analyst commented, "Heron reported disappointing 4Q21 earnings with Zynrelef reaching sales of only $0.8MM (-61% Q/Q). We... More

Heron Therapeutics (HRTX) Tops Q4 EPS by 4c

February 28, 2022 4:28 PM EST

Heron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20.66 million versus the consensus estimate of $25.59 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

... More